Showing results (51-60 of 82) with videos related to

Sort By:
Pageof 9
Communications Medicine|November 14, 2022
Adiposity and NMR-measured lipid and metabolic biomarkers among 30,000 Mexican adultsDiego Aguilar-Ramirez, William G Herrington, Jesus Alegre-Díaz, et al.
Circulation|July 14, 2018
Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney DiseaseRichard Haynes, Parminder K Judge, Natalie Staplin, et al.
BMC Nephrology|October 25, 2023
UK Kidney Association Clinical Practice Guideline: Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibition in Adults with Kidney Disease 2023 UPDATEAlistair J Roddick, Alexa Wonnacott, David Webb, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|September 15, 2024
Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trialKaitlin J Mayne, Rebecca J Sardell, Natalie Staplin, et al.
The Lancet. Diabetes & Endocrinology|October 13, 2025
Effects of empagliflozin on conventional and exploratory acute and chronic kidney outcomes: an individual participant-level meta-analysisWilliam G Herrington, Zhaojing J Che, Rebecca Sardell, et al.
Eclinicalmedicine|July 21, 2025
Effects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trialJunwen Zhou, Claire Williams, Natalie Staplin, et al.
American Journal of Nephrology|May 7, 2026
Effects of Sacubitril/Valsartan vs Irbesartan on Urine Tubular Biomarkers in CKD: Findings from the UK HARP-III TrialMichelle A Goonasekera, Greco B Malijan, Rebecca J Sardell, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|November 12, 2024
The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trialParminder K Judge, Katherine R Tuttle, Natalie Staplin, et al.
Clinical Journal of the American Society of Nephrology : CJASN|April 3, 2025
Frailty, Multimorbidity, and Polypharmacy: Exploratory Analyses of the Effects of Empagliflozin from the EMPA-KIDNEY TrialKaitlin J Mayne, Rebecca J Sardell, Natalie Staplin, et al.
Clinical Journal of the American Society of Nephrology : CJASN|July 1, 2024
Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trialKaitlin J Mayne, Rebecca J Sardell, Natalie Staplin, et al.
Pageof 9